US20100015183A1 - Transmucosal delivery devices with enhanced uptake - Google Patents

Transmucosal delivery devices with enhanced uptake Download PDF

Info

Publication number
US20100015183A1
US20100015183A1 US11/817,915 US81791507A US2010015183A1 US 20100015183 A1 US20100015183 A1 US 20100015183A1 US 81791507 A US81791507 A US 81791507A US 2010015183 A1 US2010015183 A1 US 2010015183A1
Authority
US
United States
Prior art keywords
fentanyl
subject
present
polymeric diffusion
devices
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/817,915
Other languages
English (en)
Inventor
Andrew Finn
Niraj Vasisht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Delivery Sciences International Inc
Biodelivery Sciences International Inc
Original Assignee
Bio Delivery Sciences International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38819378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100015183(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bio Delivery Sciences International Inc filed Critical Bio Delivery Sciences International Inc
Priority to US11/817,915 priority Critical patent/US20100015183A1/en
Assigned to BIODELIVERY SCIENCES INTERNATIONAL INCORPORATED reassignment BIODELIVERY SCIENCES INTERNATIONAL INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FINN, ANDREW, VASISHT, NIRAJ
Publication of US20100015183A1 publication Critical patent/US20100015183A1/en
Priority to US13/184,306 priority patent/US8147866B2/en
Assigned to BIODELIVERY SCIENCES INTERNATIONAL, INC. reassignment BIODELIVERY SCIENCES INTERNATIONAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FINN, ANDREW, VASISHT, NIRAJ
Assigned to CRG SERVICING LLC, AS ADMINISTRATIVE AGENT reassignment CRG SERVICING LLC, AS ADMINISTRATIVE AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIODELIVERY SCIENCES INTERNATIONAL, INC.
Assigned to BIODELIVERY SCIENCES INTERNATIONAL, INC. reassignment BIODELIVERY SCIENCES INTERNATIONAL, INC. PATENT AND TRADEMARK SECURITY AGREEMENTS TERMINATION Assignors: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Assigned to BIODELIVERY SCIENCES INTERNATIONAL, INC. reassignment BIODELIVERY SCIENCES INTERNATIONAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FINN, ANDREW, VASISHT, NIRAJ
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
US11/817,915 2006-07-21 2007-07-23 Transmucosal delivery devices with enhanced uptake Abandoned US20100015183A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/817,915 US20100015183A1 (en) 2006-07-21 2007-07-23 Transmucosal delivery devices with enhanced uptake
US13/184,306 US8147866B2 (en) 2006-07-21 2011-07-15 Transmucosal delivery devices with enhanced uptake

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83272506P 2006-07-21 2006-07-21
US83272606P 2006-07-21 2006-07-21
US83950406P 2006-08-23 2006-08-23
US11/817,915 US20100015183A1 (en) 2006-07-21 2007-07-23 Transmucosal delivery devices with enhanced uptake
PCT/US2007/016634 WO2008011194A2 (fr) 2006-07-21 2007-07-23 Dispositifs d'administration transmuqueuse avec absorption accrue

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016634 A-371-Of-International WO2008011194A2 (fr) 2006-07-21 2007-07-23 Dispositifs d'administration transmuqueuse avec absorption accrue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/184,306 Continuation US8147866B2 (en) 2006-07-21 2011-07-15 Transmucosal delivery devices with enhanced uptake

Publications (1)

Publication Number Publication Date
US20100015183A1 true US20100015183A1 (en) 2010-01-21

Family

ID=38819378

Family Applications (12)

Application Number Title Priority Date Filing Date
US11/817,915 Abandoned US20100015183A1 (en) 2006-07-21 2007-07-23 Transmucosal delivery devices with enhanced uptake
US13/184,306 Active US8147866B2 (en) 2006-07-21 2011-07-15 Transmucosal delivery devices with enhanced uptake
US13/413,112 Abandoned US20120164191A1 (en) 2006-07-21 2012-03-06 Transmucosal delivery devices with enhanced uptake
US14/746,168 Abandoned US20150366793A1 (en) 2006-07-21 2015-06-22 Transmucosal delivery devices with enhanced uptake
US15/198,961 Active US9597288B2 (en) 2006-07-21 2016-06-30 Transmucosal delivery devices with enhanced uptake
US15/212,912 Active US9655843B2 (en) 2006-07-21 2016-07-18 Transmucosal delivery devices with enhanced uptake
US15/429,385 Abandoned US20170312218A1 (en) 2006-07-21 2017-02-10 Transmucosal delivery devices with enhanced uptake
US15/484,682 Abandoned US20170216278A1 (en) 2006-07-21 2017-04-11 Transmucosal delivery devices with enhanced uptake
US15/801,302 Abandoned US20190111048A9 (en) 2006-07-21 2017-11-01 Transmucosal delivery devices with enhanced uptake
US16/394,647 Abandoned US20190365739A1 (en) 2006-07-21 2019-04-25 Transmucosal delivery devices with enhanced uptake
US17/209,119 Abandoned US20210275520A1 (en) 2006-07-21 2021-03-22 Transmucosal delivery device with enhanced uptake
US18/346,474 Abandoned US20240066024A1 (en) 2006-07-21 2023-07-03 Transmucosal delivery device with enhanced uptake

Family Applications After (11)

Application Number Title Priority Date Filing Date
US13/184,306 Active US8147866B2 (en) 2006-07-21 2011-07-15 Transmucosal delivery devices with enhanced uptake
US13/413,112 Abandoned US20120164191A1 (en) 2006-07-21 2012-03-06 Transmucosal delivery devices with enhanced uptake
US14/746,168 Abandoned US20150366793A1 (en) 2006-07-21 2015-06-22 Transmucosal delivery devices with enhanced uptake
US15/198,961 Active US9597288B2 (en) 2006-07-21 2016-06-30 Transmucosal delivery devices with enhanced uptake
US15/212,912 Active US9655843B2 (en) 2006-07-21 2016-07-18 Transmucosal delivery devices with enhanced uptake
US15/429,385 Abandoned US20170312218A1 (en) 2006-07-21 2017-02-10 Transmucosal delivery devices with enhanced uptake
US15/484,682 Abandoned US20170216278A1 (en) 2006-07-21 2017-04-11 Transmucosal delivery devices with enhanced uptake
US15/801,302 Abandoned US20190111048A9 (en) 2006-07-21 2017-11-01 Transmucosal delivery devices with enhanced uptake
US16/394,647 Abandoned US20190365739A1 (en) 2006-07-21 2019-04-25 Transmucosal delivery devices with enhanced uptake
US17/209,119 Abandoned US20210275520A1 (en) 2006-07-21 2021-03-22 Transmucosal delivery device with enhanced uptake
US18/346,474 Abandoned US20240066024A1 (en) 2006-07-21 2023-07-03 Transmucosal delivery device with enhanced uptake

Country Status (23)

Country Link
US (12) US20100015183A1 (fr)
EP (3) EP3067044B1 (fr)
JP (2) JP5448814B2 (fr)
KR (2) KR101329496B1 (fr)
CN (2) CN101511337B (fr)
AU (1) AU2007275581B2 (fr)
BR (2) BRPI0714712B8 (fr)
CA (1) CA2658585C (fr)
DK (1) DK2054031T3 (fr)
ES (1) ES2577390T3 (fr)
HK (2) HK1131344A1 (fr)
HR (1) HRP20160405T1 (fr)
HU (1) HUE027395T2 (fr)
IL (2) IL196529A (fr)
MX (1) MX2009000745A (fr)
NO (3) NO340668B1 (fr)
NZ (2) NZ594545A (fr)
PL (1) PL2054031T3 (fr)
RS (1) RS54764B1 (fr)
RU (3) RU2504377C2 (fr)
SI (1) SI2054031T1 (fr)
WO (1) WO2008011194A2 (fr)
ZA (1) ZA200900485B (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147866B2 (en) * 2006-07-21 2012-04-03 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
WO2013026064A1 (fr) * 2011-08-18 2013-02-21 Biodelivery Sciences International, Inc. Dispositifs mucoadhésifs anti-abus destinés à administrer de la buprénorphine
WO2013096811A2 (fr) 2011-12-21 2013-06-27 Biodelivery Sciences International, Inc. Dispositifs d'administration transmucosale de médicament pour une utilisation dans le soulagement de la douleur chronique
EP2670368A1 (fr) * 2011-02-03 2013-12-11 Pharmedica Ltd. Nouveaux films à dissolution orale pour administration d'insuline, pour traitement du diabète
US8815911B2 (en) * 2012-05-02 2014-08-26 Orexo Ab Alfentanil composition for the treatment of acute pain
US9216175B2 (en) 2013-09-10 2015-12-22 Insys Pharma, Inc. Sublingual buprenorphine spray
US9642848B2 (en) 2014-07-08 2017-05-09 Insys Development Company, Inc. Sublingual naloxone spray
US9687454B2 (en) 2009-08-07 2017-06-27 Indivior Uk Limited Sublingual and buccal film compositions
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2021163529A2 (fr) 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Procédés de traitement avec de la buprénorphine

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US20110033542A1 (en) * 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP2063864A4 (fr) 2006-09-20 2012-03-14 Monosol Rx Llc Film hydrosoluble comestible contenant un agent aromatisant réduisant la mousse
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
ES2663777T3 (es) * 2008-06-23 2018-04-17 Biodelivery Sciences International, Inc. Dispositivos de administración mucosa multidireccionales y métodos de uso
US8282954B2 (en) 2008-12-15 2012-10-09 Monosol Rx, Llc Method for manufacturing edible film
CN102480958B (zh) 2009-06-12 2015-08-19 Cynapsus疗法有限公司 舌下阿扑吗啡
JP5819949B2 (ja) 2010-06-10 2015-11-24 ミダテック リミテッド ナノ粒子フィルム送達システム
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
KR101946774B1 (ko) 2010-12-16 2019-02-11 선오비온 파마슈티컬스 인코포레이티드 설하 필름
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
HUE056309T2 (hu) 2011-09-19 2022-02-28 Orexo Ab Buprenorfint és naloxont tartalmazó szublingvális, abúzus-rezisztens tabletták
EP3485880A1 (fr) 2012-04-17 2019-05-22 Purdue Pharma LP Systèmes et procédés pour le traitement d'une réponse pharmacodynamique indésirable induite par opioïdes
WO2014042875A1 (fr) 2012-09-12 2014-03-20 Boston Scientific Scimed, Inc. Revêtement adhésif anti-migration pour endoprothèse vasculaire
CN109303628B (zh) 2013-08-08 2021-08-10 波士顿科学国际有限公司 防止支架移位的可溶性或可降解粘合剂聚合物
WO2016086095A1 (fr) * 2014-11-25 2016-06-02 Biodelivery Sciences International, Inc. Timbres, procédés de formation et de test de timbres d'administration d'agent pharmaceutique
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
EP3267875A4 (fr) 2015-03-12 2018-12-05 Chrono Therapeutics Inc. Système d'entrée d'état de manque et de support
CA3127926A1 (fr) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methodes de traitement de la maladie de parkinson par l'administration d'apomorphine a une muqueuse orale
US20170065580A1 (en) * 2015-09-09 2017-03-09 Biodelivery Sciences International, Inc. Methods of safely transitioning a subject to buprenorphine
CA3044944C (fr) * 2015-11-25 2021-06-22 Tbm Company Film buccal hemostatique et de protection des plaies
BR112018072539A2 (pt) 2016-05-05 2019-03-26 Aquestive Therapeutics, Inc. composições de epinefrina de administração aumentada
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN105997955B (zh) 2016-06-28 2017-09-12 力品药业（厦门）有限公司 一种帕洛诺司琼口腔膜剂及其制备方法
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
KR101912380B1 (ko) * 2017-03-15 2018-10-26 (주)바이오일레븐 프로바이오틱스의 방출 및 프로바이오틱스 효소 활성의 유지를 위한 점막점착성 장치
EP3691610A1 (fr) 2017-10-07 2020-08-12 Zim Laboratories Limited Procédé de préparation d'un film bi ou multicouche, film multicouche produit à partir de celui-ci et appareil de production de tels films multicouches
JP2021515034A (ja) * 2018-02-22 2021-06-17 アビオール、インコーポレイテッド 経粘膜フィルム組成物ならびにそれを作製及び使用する方法
CA3101966A1 (fr) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Procedes et systemes d'administration de medicament
WO2020077235A1 (fr) * 2018-10-11 2020-04-16 Indivior Uk Limited Buprénorphine pour traiter une dépression respiratoire
US11318107B2 (en) 2019-02-22 2022-05-03 Avior, Inc. Pharmaceutical active-containing film delivery device for oral transmucosal administration
US11179331B1 (en) 2020-04-21 2021-11-23 Cure Pharmaceutcai Holding Corp Oral soluble film containing sildenafil citrate

Citations (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292299A (en) * 1978-11-06 1981-09-29 Teijin Limited Slow-releasing medical preparation to be administered by adhering to a wet mucous surface
US4552751A (en) * 1980-10-17 1985-11-12 Ono Pharmaceutical Co., Ltd. Long-lasting multi-layered film preparation
US4765983A (en) * 1985-06-05 1988-08-23 Yamanouchi Pharmaceutical Co., Ltd. Adhesive medical tapes for oral mucosa
US4990339A (en) * 1987-11-16 1991-02-05 H. B. Fuller Company Dermal treatment film
US5064654A (en) * 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5116621A (en) * 1989-12-25 1992-05-26 Lederle (Japan), Ltd. Anti-inflammatory analgesic patch
US5137729A (en) * 1989-01-31 1992-08-11 Nitto Denko Corporation Drug preparation applicable to oral mucosa
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5780047A (en) * 1995-06-27 1998-07-14 Kao Corporation Patch
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US5855908A (en) * 1984-05-01 1999-01-05 University Of Utah Research Foundation Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6255502B1 (en) * 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6277384B1 (en) * 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US20020034554A1 (en) * 1999-12-16 2002-03-21 Tsung-Min Hsu Dual enhancer composition for topical and transdermal drug delivery
US20020142036A1 (en) * 1999-07-13 2002-10-03 Herbert Rupprecht Active substance-containing multi-layer film of hydrophilic polymers crosslinked in situ
US20020160043A1 (en) * 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
US20030044446A1 (en) * 2001-08-16 2003-03-06 Mucoadhesive Erodible Drug Delivery Device For Controlled Admn. Of Pharmaceuticals & Other Acti Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US6562363B1 (en) * 1997-09-26 2003-05-13 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US20040024003A1 (en) * 1999-12-14 2004-02-05 Bodo Asmussen Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6719997B2 (en) * 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US20040151774A1 (en) * 2002-10-31 2004-08-05 Pauletti Giovanni M. Therapeutic compositions for drug delivery to and through covering epithelia
US20040180080A1 (en) * 2001-03-15 2004-09-16 Kazuyoshi Furusawa Fentanyl compound-containing edible patch to be applied to oral mucosa
US20050042281A1 (en) * 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20050085440A1 (en) * 2002-03-19 2005-04-21 Birch Philip J. Formulation
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
US20070148097A1 (en) * 2005-12-13 2007-06-28 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
US20110262522A1 (en) * 2006-07-21 2011-10-27 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB981372A (en) 1960-05-04 1965-01-27 Pfizer Ltd Pharmaceutical formulations for oral administration to animals
US3640741A (en) 1970-02-24 1972-02-08 Hollister Inc Composition containing gel
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
GB2042888B (en) 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4713239A (en) 1979-05-29 1987-12-15 Vsesojuny Kardiologichesky Nauchny Tsentr Adkaemii Meditsinski Nauk Sssr Antianginal film and method of treating ischemic heart disease
US4285934A (en) 1979-07-13 1981-08-25 Tinnell James E Treatment for herpes virus
JPS56100714A (en) 1980-01-16 1981-08-12 Teijin Ltd Pharmaceutical adhering to oral mucous membrane or nasal mucous membrane
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4381296A (en) 1980-06-23 1983-04-26 Tinnell James E Treatment for herpes virus
JPS5758615A (en) 1980-09-26 1982-04-08 Nippon Soda Co Ltd Film agnent and its preparation
JPS57110254A (en) 1980-12-29 1982-07-09 Teijin Ltd Coating agent of injured membrane part of oral cavity
AU8533582A (en) 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
CH653550A5 (de) 1981-10-20 1986-01-15 Sandoz Ag Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich.
US4518721A (en) 1982-03-26 1985-05-21 Richardson-Vicks Inc. Hydrophilic denture adhesive
JPS5948409A (ja) 1982-09-10 1984-03-19 Teikoku Seiyaku Kk 矯正的歯牙移動促進剤
CA1208558A (fr) 1982-10-07 1986-07-29 Kazuo Kigasawa Medicament oral
JPS604120A (ja) 1983-06-22 1985-01-10 Shionogi & Co Ltd 作用持続型ピナシジル製剤
JPS60116630A (ja) 1983-11-29 1985-06-24 Nitto Electric Ind Co Ltd 口腔内製剤
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4713246A (en) 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
US4740365A (en) 1984-04-09 1988-04-26 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
EP0186019B1 (fr) 1984-12-22 1993-10-06 Schwarz Pharma Ag Pansement médicamenteux
JPH0653659B2 (ja) 1985-07-22 1994-07-20 ニチバン株式会社 粘膜付着製剤
GB8521494D0 (en) 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
JPS6256420A (ja) 1985-09-05 1987-03-12 Teijin Ltd フイルム状付着性製剤
JPH07553B2 (ja) 1985-12-09 1995-01-11 佐藤製薬株式会社 フイルム状製剤
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
JPH0729915B2 (ja) 1986-02-01 1995-04-05 帝國製薬株式会社 シ−ト状口腔内貼付剤
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
CH668187A5 (de) 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
JPH0794384B2 (ja) 1986-09-01 1995-10-11 帝国製薬株式会社 徐放性口腔内用製剤
US5196202A (en) 1986-09-01 1993-03-23 Teikoku Seiyaku Kabushiki Kaisha Sustained release dosage form
US4906463A (en) 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
JPH0744940B2 (ja) 1986-12-24 1995-05-17 ライオン株式会社 口腔貼付用基材
DE3714074A1 (de) 1987-04-28 1988-11-10 Hoechst Ag Grundlage fuer schleimhaut- und prothesenhaft-pasten, verfahren zu ihrer herstellung sowie pasten auf basis dieser grundlage
US4867970A (en) 1987-05-21 1989-09-19 E. R. Squibb & Sons, Inc. Moistureless oral drug delivery formulation and method for preparing same
JPS63310818A (ja) 1987-06-12 1988-12-19 Sato Seiyaku Kk シ−ト状口腔粘膜付着製剤
US4915948A (en) 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US5059189A (en) 1987-09-08 1991-10-22 E. R. Squibb & Sons, Inc. Method of preparing adhesive dressings containing a pharmaceutically active ingredient
JPS6471812A (en) 1987-09-11 1989-03-16 Sekisui Chemical Co Ltd Medical application agent
JP2635336B2 (ja) 1987-09-30 1997-07-30 帝國製薬株式会社 徐放性口腔内用製剤
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
JP2685055B2 (ja) 1988-03-08 1997-12-03 帝國製薬株式会社 シコン含有口腔粘膜貼付剤
US4900552A (en) 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US5081157A (en) 1988-05-02 1992-01-14 Zila Pharmaceuticals, Inc. Compositions and in situ methods for forming films on body tissue
US5081158A (en) 1988-05-02 1992-01-14 Zila Pharmaceuticals, Inc. Compositions and in situ methods for forming films on body tissue
US5047244A (en) 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
JPH0645536B2 (ja) 1989-01-31 1994-06-15 日東電工株式会社 口腔粘膜貼付剤および口腔粘膜貼付製剤
US5750136A (en) 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US5298258A (en) 1989-12-28 1994-03-29 Nitto Denko Corporation Acrylic oily gel bioadhesive material and acrylic oily gel preparation
JP2879695B2 (ja) 1990-02-22 1999-04-05 日本曹達株式会社 口腔内粘膜付着性フィルム製剤
JP2930374B2 (ja) 1990-06-28 1999-08-03 東亜医薬品工業株式会社 口腔内貼着型膜製剤
US5332576A (en) 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5254345A (en) 1991-10-11 1993-10-19 Merck & Co., Inc. Poly(orthocarbonate acetal) bioerodible polymers
US5298256A (en) 1992-04-28 1994-03-29 Corint, Ltd. Desmopressin buccal patch composition
US5436701A (en) 1992-06-19 1995-07-25 Canon Kabushiki Kaisha Image forming method, image forming apparatus and apparatus unit
GB2273044B (en) 1992-12-02 1997-04-09 Pacific Chem Co Ltd Medicinal patches for percutaneous administration
EP0708627B1 (fr) 1993-07-09 2000-02-02 Cygnus, Inc. Procede et dispositif therapeutique d'administration de substitut de la nicotine par voie transcutanee ou buccale
AU7568394A (en) 1993-08-19 1995-03-14 Cygnus Therapeutic Systems Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
US5540930A (en) 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
FR2712807B1 (fr) 1993-11-24 1996-02-23 Vetoquinol Sa Composition solide mucoadhésive, thérapeutique ou hygiénique, pour administration par application sur la muqueuse buccale ou nasale .
DE4341442C2 (de) 1993-12-04 1998-11-05 Lohmann Therapie Syst Lts Vorrichtung zur kontrollierten Freisetzung von Wirkstoffen sowie ihre Verwendung
US5466465A (en) 1993-12-30 1995-11-14 Harrogate Holdings, Limited Transdermal drug delivery system
US5679714A (en) 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
RU2142273C1 (ru) 1994-03-21 1999-12-10 Браун Томсен Йохн Гель для лечения кожных заболеваний и для дезинфекции кожи
AU2703795A (en) 1994-06-23 1996-01-19 Procter & Gamble Company, The Treatment of nicotine craving and/or smoking withdrawal symptoms with a transdermal or transmucosal composition containing nicotine and caffeine or xanthine
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
JP2791317B2 (ja) 1995-12-26 1998-08-27 株式会社三和化学研究所 多層フィルム製剤
FR2742989B1 (fr) 1995-12-29 1998-01-23 Adir Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
DE19652188C2 (de) 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ATE288743T1 (de) 1998-04-29 2005-02-15 Virotex Corp Pharmazeutische trägervorrichtung welche zur verabreichung von wirkstoffen an schleimhautoberflächen geeignet ist
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
HUP0103543A2 (hu) * 1998-10-02 2002-01-28 3M Innovative Properties Company Nyálkahártyán megtapadó hatóanyag bejuttató rendszerek és ezek alkalmazása állatok kezelésére
US20030170195A1 (en) 2000-01-10 2003-09-11 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
WO2000041538A2 (fr) 1999-01-14 2000-07-20 Noven Pharmaceuticals, Inc. Compositions et procedes pour l'administration de medicament
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6284262B1 (en) 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
US6319510B1 (en) * 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
EP2092936B1 (fr) 2000-02-08 2013-03-20 Euro-Celtique S.A. Compositions orales inviolables comprenant des agonistes opioïdes
JP2004515455A (ja) 2000-05-05 2004-05-27 ペイン・セラピューティクス・インコーポレイテッド オピオイドアンタゴニスト組成物および投薬形態
WO2001089476A1 (fr) * 2000-05-19 2001-11-29 Npd Llc Gommes a macher, pastilles, bonbons, tablettes, liquides et sprays destines a une administration efficace de medicaments et de supplements dietetiques
GB0026137D0 (en) 2000-10-25 2000-12-13 Euro Celtique Sa Transdermal dosage form
WO2002064197A1 (fr) 2001-02-09 2002-08-22 Hager & Werken Gmbh & Co. Kg Seringue d'injection et receptacle jetable pour ensembles aiguilles
DK1397095T3 (da) 2001-05-01 2009-03-09 Euro Celtique Sa Misbrugsresistente, opioid-holdige transdermale systemer
WO2002092060A1 (fr) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Forme posologique d'opioides a liberation prolongee empechant la consommation abusive
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
IL160222A0 (en) 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US7910641B2 (en) 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US20030194420A1 (en) * 2002-04-11 2003-10-16 Richard Holl Process for loading a drug delivery device
AU2003234395B2 (en) 2002-05-13 2008-01-24 Endo Pharmaceuticals Inc. Abuse-resistant opioid solid dosage form
AU2003251482A1 (en) 2002-06-10 2003-12-22 Euro-Celtique, S.A. Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
EP1530469B1 (fr) 2002-08-20 2009-02-25 Euro-Celtique S.A. Forme posologique transdermique comprenant un principe actif, un sel et une forme de base libre d'un antagoniste
US20050013845A1 (en) 2002-11-12 2005-01-20 Warren Stephen L. Adhesive bioerodible ocular drug delivery system
ES2310262T3 (es) 2002-12-13 2009-01-01 Euro-Celtique S.A. Regimen de dosificacion de bruprenorfina transdermica para analgesia.
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
US20040191301A1 (en) 2003-03-27 2004-09-30 Van Duren Albert Philip Transdermal device having a phase change material
US20040213828A1 (en) 2003-04-23 2004-10-28 Smith David J. Pain relief lollipop compositions and methods
MXPA05011703A (es) 2003-04-30 2006-01-23 Purdue Pharma Lp Forma de dosis transdermica resistente a los retardadores que comprende un componente de agente activo y un componente de agente adverso en el sitio distal de la capa del agente activo.
US20040219195A1 (en) 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US7182955B2 (en) 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
JP5137286B2 (ja) * 2003-06-10 2013-02-06 帝國製薬株式会社 フェンタニル含有口腔粘膜貼付剤
KR20060037234A (ko) 2003-07-11 2006-05-03 마쯔시다덴기산교 가부시키가이샤 광픽업용 렌즈장치 및 이를 이용한 정보기록 재생장치
MXPA06001776A (es) 2003-08-15 2007-09-07 Qlt Usa Inc Sistema de suministro de farmaco transmucosal biocorrosivo, adhesivo.
US20080317828A1 (en) 2003-09-24 2008-12-25 Kazuyoshi Furusawa Fentanyl compound-containing edible patch to be applied to oral mucosa
ES2626784T3 (es) 2003-10-28 2017-07-26 Noven Pharmaceuticals, Inc. Dispositivo de administración transdérmica de fármacos
WO2005044243A2 (fr) 2003-10-30 2005-05-19 Alza Corporation Systemes analgesiques transdermiques reduisant les risques d'abus de consommation
DK1691892T3 (da) 2003-12-09 2007-06-25 Euro Celtique Sa Anbrudsbestandig, coekstruderet doseringsform, der indeholder et aktivt middel og et modvirkende middel, og fremgangsmåde til fremstilling af samme
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
ATE426399T1 (de) 2004-02-23 2009-04-15 Euro Celtique Sa Missbrauchsichere transdermale abgabevorrichtung fur opioide, enthaltend opioidantagonist in form von mikrokugelchen
EP1584335A3 (fr) 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Combinaison de substances actives comprenant un composé carbinol et un opioïde
US20060069086A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7827983B2 (en) 2004-12-20 2010-11-09 Hewlett-Packard Development Company, L.P. Method for making a pharmaceutically active ingredient abuse-prevention device
DE102005007859A1 (de) 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
GB0514043D0 (en) 2005-07-08 2005-08-17 Arakis Ltd Fentanyl formulation
EP1897543A1 (fr) 2006-08-30 2008-03-12 Euro-Celtique S.A. Gaufre de buprénorphine pour la thérapie de substitution
DK2248519T3 (en) 2006-10-02 2018-01-02 Applied Pharma Res Non-mucoadhesive film dosage forms
GB0620661D0 (en) 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
CA2677281C (fr) 2007-02-09 2019-10-29 Durect Corporation Formes posologiques par voie orale comprenant du sufentanile et de la naloxone
GB2447015A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
ES2663777T3 (es) 2008-06-23 2018-04-17 Biodelivery Sciences International, Inc. Dispositivos de administración mucosa multidireccionales y métodos de uso
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
JP6158810B2 (ja) * 2011-08-18 2017-07-05 バイオデリバリー サイエンシズ インターナショナル，インコーポレーテッド ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス
US9901539B2 (en) * 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief

Patent Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4292299A (en) * 1978-11-06 1981-09-29 Teijin Limited Slow-releasing medical preparation to be administered by adhering to a wet mucous surface
US4552751A (en) * 1980-10-17 1985-11-12 Ono Pharmaceutical Co., Ltd. Long-lasting multi-layered film preparation
US5855908A (en) * 1984-05-01 1999-01-05 University Of Utah Research Foundation Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US4765983A (en) * 1985-06-05 1988-08-23 Yamanouchi Pharmaceutical Co., Ltd. Adhesive medical tapes for oral mucosa
US4990339A (en) * 1987-11-16 1991-02-05 H. B. Fuller Company Dermal treatment film
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5064654A (en) * 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5137729A (en) * 1989-01-31 1992-08-11 Nitto Denko Corporation Drug preparation applicable to oral mucosa
US5116621A (en) * 1989-12-25 1992-05-26 Lederle (Japan), Ltd. Anti-inflammatory analgesic patch
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5780047A (en) * 1995-06-27 1998-07-14 Kao Corporation Patch
US6255502B1 (en) * 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US6159498A (en) * 1996-10-18 2000-12-12 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces
US6562363B1 (en) * 1997-09-26 2003-05-13 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US6277384B1 (en) * 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6200604B1 (en) * 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US20020142036A1 (en) * 1999-07-13 2002-10-03 Herbert Rupprecht Active substance-containing multi-layer film of hydrophilic polymers crosslinked in situ
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20040024003A1 (en) * 1999-12-14 2004-02-05 Bodo Asmussen Flat medicinal preparation for transmucosal administration of oxycodon or a comparable active ingredient in the oral cavity, for use in pain therapy and in addiction therapy
US20020034554A1 (en) * 1999-12-16 2002-03-21 Tsung-Min Hsu Dual enhancer composition for topical and transdermal drug delivery
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20030161870A1 (en) * 1999-12-16 2003-08-28 Tsung-Min Hsu Dual enhancer composition for topical and transdermal drug delivery
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6719997B2 (en) * 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US20020160043A1 (en) * 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
US20040180080A1 (en) * 2001-03-15 2004-09-16 Kazuyoshi Furusawa Fentanyl compound-containing edible patch to be applied to oral mucosa
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20030044446A1 (en) * 2001-08-16 2003-03-06 Mucoadhesive Erodible Drug Delivery Device For Controlled Admn. Of Pharmaceuticals & Other Acti Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20050085440A1 (en) * 2002-03-19 2005-04-21 Birch Philip J. Formulation
US20040151774A1 (en) * 2002-10-31 2004-08-05 Pauletti Giovanni M. Therapeutic compositions for drug delivery to and through covering epithelia
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US20050042281A1 (en) * 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
US20070148097A1 (en) * 2005-12-13 2007-06-28 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
US20110262522A1 (en) * 2006-07-21 2011-10-27 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
US8147866B2 (en) * 2006-07-21 2012-04-03 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Fine et al., Journal of Palliative Medicine, 1998, 1(1), 55-63. *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147866B2 (en) * 2006-07-21 2012-04-03 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
US9655843B2 (en) 2006-07-21 2017-05-23 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
US9597288B2 (en) 2006-07-21 2017-03-21 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
US11135216B2 (en) 2009-08-07 2021-10-05 Indivior Uk Limited Sublingual and buccal film compositions
US9687454B2 (en) 2009-08-07 2017-06-27 Indivior Uk Limited Sublingual and buccal film compositions
EP2670368A1 (fr) * 2011-02-03 2013-12-11 Pharmedica Ltd. Nouveaux films à dissolution orale pour administration d'insuline, pour traitement du diabète
EP2670368A4 (fr) * 2011-02-03 2015-04-15 Pharmedica Ltd Nouveaux films à dissolution orale pour administration d'insuline, pour traitement du diabète
EP2744572A4 (fr) * 2011-08-18 2015-06-03 Biodelivery Sciences Int Inc Dispositifs mucoadhésifs anti-abus destinés à administrer de la buprénorphine
AU2018200402B2 (en) * 2011-08-18 2019-04-18 Biodelivery Sciences International Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US20220016109A1 (en) * 2011-08-18 2022-01-20 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US20160339016A1 (en) * 2011-08-18 2016-11-24 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
WO2013026064A1 (fr) * 2011-08-18 2013-02-21 Biodelivery Sciences International, Inc. Dispositifs mucoadhésifs anti-abus destinés à administrer de la buprénorphine
US20200129503A1 (en) * 2011-08-18 2020-04-30 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US8703177B2 (en) 2011-08-18 2014-04-22 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
EA033256B1 (ru) * 2011-08-18 2019-09-30 Байоделивери Сайенсиз Интернэшнл, Инк. Не вызывающие зависимость двухслойные устройства для трансмукозальной доставки бупренорфина
US20190240214A1 (en) * 2011-08-18 2019-08-08 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
WO2013096811A2 (fr) 2011-12-21 2013-06-27 Biodelivery Sciences International, Inc. Dispositifs d'administration transmucosale de médicament pour une utilisation dans le soulagement de la douleur chronique
US9782396B2 (en) 2012-05-02 2017-10-10 Orexo Ab Alfentanil composition for the treatment of acute pain
US8815911B2 (en) * 2012-05-02 2014-08-26 Orexo Ab Alfentanil composition for the treatment of acute pain
US9345698B2 (en) 2012-05-02 2016-05-24 Orexo Ab Alfentanil composition for the treatment of acute pain
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
US9216175B2 (en) 2013-09-10 2015-12-22 Insys Pharma, Inc. Sublingual buprenorphine spray
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US9642848B2 (en) 2014-07-08 2017-05-09 Insys Development Company, Inc. Sublingual naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2021163529A2 (fr) 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Procédés de traitement avec de la buprénorphine

Also Published As

Publication number Publication date
JP2013151549A (ja) 2013-08-08
US9597288B2 (en) 2017-03-21
IL196529A0 (en) 2009-11-18
US20160310409A1 (en) 2016-10-27
US20150366793A1 (en) 2015-12-24
ZA200900485B (en) 2011-08-31
EP2054031B1 (fr) 2016-04-06
DK2054031T3 (en) 2016-05-17
KR20090033903A (ko) 2009-04-06
NO344719B1 (no) 2020-03-23
KR101230804B1 (ko) 2013-02-08
US20210275520A1 (en) 2021-09-09
HRP20160405T1 (hr) 2016-07-01
NZ594545A (en) 2012-12-21
WO2008011194A3 (fr) 2008-05-15
CN103550136A (zh) 2014-02-05
NO340668B1 (no) 2017-05-29
US20160324768A1 (en) 2016-11-10
US20110262522A1 (en) 2011-10-27
IL220722A (en) 2016-04-21
BRPI0714712B8 (pt) 2021-05-25
EP2054031A2 (fr) 2009-05-06
MX2009000745A (es) 2009-04-16
US20170312218A1 (en) 2017-11-02
RU2009106177A (ru) 2010-08-27
JP2009544619A (ja) 2009-12-17
BRPI0714712A2 (pt) 2013-07-16
US20180133210A1 (en) 2018-05-17
KR101329496B1 (ko) 2013-11-13
RU2019118034A (ru) 2020-12-10
EP3566692A1 (fr) 2019-11-13
CA2658585C (fr) 2011-03-01
CA2658585A1 (fr) 2008-01-24
KR20120102121A (ko) 2012-09-17
NZ574361A (en) 2012-02-24
BR122020000250B1 (pt) 2021-02-02
US9655843B2 (en) 2017-05-23
JP5689144B2 (ja) 2015-03-25
AU2007275581A1 (en) 2008-01-24
HK1193566A1 (zh) 2014-09-26
RS54764B1 (sr) 2016-10-31
NO20200273A1 (no) 2009-03-12
RU2504377C2 (ru) 2014-01-20
HUE027395T2 (hu) 2016-10-28
BR122020000250B8 (pt) 2021-07-27
BRPI0714712B1 (pt) 2020-11-17
IL196529A (en) 2013-10-31
JP5448814B2 (ja) 2014-03-19
HK1131344A1 (en) 2010-01-22
US20240066024A1 (en) 2024-02-29
NO20090278L (no) 2009-03-12
US20190365739A1 (en) 2019-12-05
EP3067044B1 (fr) 2019-03-27
RU2013141051A (ru) 2015-03-20
US8147866B2 (en) 2012-04-03
CN103550136B (zh) 2016-04-13
SI2054031T1 (sl) 2016-09-30
EP3067044A1 (fr) 2016-09-14
CN101511337A (zh) 2009-08-19
US20170216278A1 (en) 2017-08-03
AU2007275581B2 (en) 2011-09-08
PL2054031T3 (pl) 2016-09-30
ES2577390T3 (es) 2016-07-14
WO2008011194A2 (fr) 2008-01-24
NO20170380A1 (no) 2009-03-12
US20190111048A9 (en) 2019-04-18
US20120164191A1 (en) 2012-06-28
CN101511337B (zh) 2013-12-11

Similar Documents

Publication Publication Date Title
US20210275520A1 (en) Transmucosal delivery device with enhanced uptake
EP2744572B1 (fr) Dispositifs mucoadhésifs anti-abus destinés à administrer de la buprénorphine
AU2011205222B2 (en) Transmucosal delivery devices with enhanced uptake

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIODELIVERY SCIENCES INTERNATIONAL INCORPORATED,NO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FINN, ANDREW;VASISHT, NIRAJ;REEL/FRAME:023729/0162

Effective date: 20060907

AS Assignment

Owner name: BIODELIVERY SCIENCES INTERNATIONAL, INC., NORTH CA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FINN, ANDREW;VASISHT, NIRAJ;REEL/FRAME:027825/0384

Effective date: 20120301

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT, TEXAS

Free format text: SECURITY INTEREST;ASSIGNOR:BIODELIVERY SCIENCES INTERNATIONAL, INC.;REEL/FRAME:041370/0891

Effective date: 20170221

AS Assignment

Owner name: BIODELIVERY SCIENCES INTERNATIONAL, INC., NORTH CA

Free format text: PATENT AND TRADEMARK SECURITY AGREEMENTS TERMINATION;ASSIGNOR:CRG SERVICING LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:049374/0336

Effective date: 20190528

AS Assignment

Owner name: BIODELIVERY SCIENCES INTERNATIONAL, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FINN, ANDREW;VASISHT, NIRAJ;REEL/FRAME:062637/0166

Effective date: 20120301